**All Interactions with Nelfinavir (Viracept)**

| **Coadministered Drug** | **Dose of Drug** | **Dose of Nelfinavir** | **Effect on Drug Levels** | **Effect on Nelfinavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| --- | --- | --- | --- | --- | --- | --- | --- |
| Amiodarone[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24) | - | - | Not studied; may increase amiodarone levels | - | Increased amiodarone effects (eg, hypotension, bradycardia, cardiac arrhythmias) | Inhibition of CYP450 3A4 by nelfinavir | Monitor and adjust amiodarone as indicated |
| Amprenavir[111](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#111)  (APV)(Agenerase) | 1200 mg BID with efavirenz 600 mg QD | 1250 mg BID | Amprenavir clearance: decreased 41% | Not studied | - | Induction of CYP450 3A4 by amprenavir or efavirenz | Dose adjustment not established |
| Amprenavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#60)  (APV)(Agenerase) | 750 mg or 800 mg TID x 2 weeks (fed) | 750 mg TID x 2 weeks (fed) | No significant change | Nelfinavir AUC: increased 15%; Cmax: no significant change | - | - | No dose adjustment necessary |
| Amprenavir[60](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#60)  (APV)(Agenerase) | 750 mg or 800 mg TID x 2 weeks (fed) | 750 mg TID x 2 weeks (fed) | Amprenavir AUC: no significant change; Cmax: no significant change; Cmin: increased 189% | Nelfinavir AUC: increased 15%; Cmax: no significant change; Cmin: no significant change | Increased amprenavir effects | Inhibition of CYP450 3A4 by both drugs | No dose adjustment necessary |
| Astemizole[254](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#254)  (Hismanal) | - | - | Not studied; may increase astemizole levels | - | Increased astemizole effects (eg, cardiac arrhythmias) | Inhibition of CYP450 3A4 by nelfinavir | Do not coadminister  *Alternative Agents*:  **Cetirizine Fexofenadine Loratadine** |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Nelfinavir** | **Effect on Drug Levels** | **Effect on Nelfinavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Atazanavir[157](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#157)  (ATV)(Reyataz) | 400 mg QD x 7 d | 1250 mg BID x 14 d | No significant change | Nelfinavir Cmin: increased 57%; M8 AUC: increased 30%; Cmax: increased 24%; Cmin: increased 124% | - | Inhibition of CYP450 3A4 by atazanavir | No dose adjustment necessary |
| Atorvastatin[219](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#219),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24) | - | - | Atorvastatin AUC: increased 71%; Cmax: increased 122% | Not studied | Increased atorvastatin effects (eg, myopathy, rhabdomyolysis) | Inhibition of CYP450 3A4 by nelfinavir | Avoid combination if possible; may consider low dose atorvastatin or alternative agents; monitor for myopathy  *Alternative Agents*:  **Pravastatin** |
| Bosentan[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#727) | - | - | - | - | Possible increased bosentan effects | - | Start low and titrate bosentan to effect. If patient has been on protease inhibitor (other than unboosted atazanavir) for more than 10 days, start bosentan at 62.5 mg daily or every other day. If patient is currently on bosentan and requires a PI (other than unboosted atazanavir), stop bosentan for at least 36 hours prior to initiating ART. Wait 10 days and then resume bosentan starting with 62.5 mg daily or every other day. |
| Carbamazepine[254](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#254)  (others)(Tegretol) | - | - | Not studied; may increase carbamazepine levels | Not studied; may decrease nelfinavir levels | - | Induction of CYP450 3A4 by carbamazepine; inhibition of CYP450 3A4 by nelfinavir | Avoid combination if possible; consider alternative agents; monitor carbamazepine levels and adjust as indicated  *Alternative Agents*:  **Gabapentin Lamotrigine Tiagabine Topiramate** |
| Caspofungin[384](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#384)  (Cancidas) | 50 mg IV x 14 days | 1250 mg BID x 14 days | No significant change | Not studied | - | - | No dose adjustment necessary |
| Cerivastatin[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24) | - | - | Not studied; may increase cerivastatin levels | - | Increased cerivastatin effects (eg, myopathy, rhabdomyolysis) | Inhibition of CYP450 3A4 by nelfinavir | Do not coadminister  *Alternative Agents*:  **Atorvastatin Pravastatin** |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Nelfinavir** | **Effect on Drug Levels** | **Effect on Nelfinavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Cisapride[294](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#294),[254](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#254),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Propulsid) | - | - | Not studied; may increase cisapride levels | - | Increased cisapride effects (eg, cardiac arrhythmias) | Inhibition of CYP450 3A4 by nelfinavir | Do not coadminister  *Alternative Agents*:  **Metoclopramide** |
| Colchicine[559](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#559)  (Colcrys) | - | - | - | - | Increased colchicine effects | Inhibition of P450 3A4 by nelfinavir | For treatment of gout, reduce colchicine dosage to 0.6 mg x 1 then 0.3 mg one hour later. Dose not to be repeated no earlier than 3 days. For prophylaxis of gout, reduce colchicine dosage to 0.3 mg QD if on 0.6 mg BID prior to PI therapy or reduce colchicine dose to 0.3 mg QOD if on 0.6 mg QD prior to PI therapy. For treatment of familial Mediterranean fever: Do not exceed colchicine 0.6 mg once daily or 0.3 mg BID. Do not coadminister in patients with hepatic or renal impairment. |
| Cyclosporine[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Neoral, Sandimmune) | - | - | Not studied; may increase cyclosporine levels | - | Cyclosporine toxicity (eg, excessive bone marrow suppression, nephrotoxicity) | Inhibition of CYP450 3A4 by nelfinavir | Monitor and adjust cyclosporine as indicated |
| Delavirdine[89](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#89)  (DLV)(Rescriptor) | 400 mg TID | 750 mg TID | Delavirdine AUC: decreased 42%; Cmin: decreased 52% | Nelfinavir AUC: increased 72% | Increased nelfinavir effects | Inhibition of CYP450 3A4 by delavirdine | Dose adjustment not established |
| Desipramine[260](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#260)  (Norpramin) | - | - | May increase desipramine levels | - | Increased desipramine effects (eg, dry mouth, dizziness, urinary retention) | Inhibition of CYP450 2D6 by nelfinavir | Monitor and adjust desipramine as indicated |
| Didanosine[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#19),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (ddI)(Videx) | 200 mg (buffered formulation) x 1 dose | 750 mg x 1 dose | Not studied | No significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Nelfinavir** | **Effect on Drug Levels** | **Effect on Nelfinavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Didanosine[19](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#19)  (ddI)(Videx) | 200 mg x 1 dose | 750 mg x 1 dose | Not studied | No significant change | - | - | No dose adjustment necessary |
| Dofetilide[316](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#316)  (Tikosyn) | - | - | Not studied; may increase dofetilide levels | - | Increased dofetilide effects (eg, cardiac arrhythmias) | Inhibition of CYP450 3A4 by nelfinavir | Monitor and adjust dofetilide as indicated |
| Efavirenz[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24),[21](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#21),[70](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#70),[71](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#71)  (EFV)(Sustiva) | 600 mg QD x 7 days | 750 mg Q8H x 7 days | No significant change | Nelfinavir AUC: increased 20%; Cmax: increased 21%.M8 AUC: decreased 37%; Cmax: decreased 40% | - | - | No dose adjustment necessary |
| Efavirenz[156](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#156)  (EFV)(Sustiva) | 600 mg QHS | 750 mg TID | - | Nelfinavir clearance: no significant changeM8 clearance: increased 43% | - | - | No dose adjustment necessary |
| Emivirine[267](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#267)  (MKC-442) | - | - | - | Nelfinavir AUC: decreased 30% | - | - | Dose adjustment not established |
| Ergotamine[254](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#254),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Cafergot, Ergot derivatives)(Cafergot, others) | - | - | Not studied; may increase ergotamine levels | - | Increased ergotamine effects (eg, ergotism) | Inhibition of CYP450 3A4 by nelfinavir | Do not coadminister  *Alternative Agents*:  **5-HT agonists ("triptans")** |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Nelfinavir** | **Effect on Drug Levels** | **Effect on Nelfinavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ethinyl estradiol/norethindrone acetate[254](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#254),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (others)(Ortho-Novum) | Ethinyl estradiol (EE) 35 mcg/ Norethindrone (N) 0.4 mg QD x 15 days | 750 mg Q8H x 7 days | Ethinyl estradiol AUC: decreased 47%; Cmax: decreased 28%;Norethindrone AUC: decreased 18%; Cmax: no significant change | - | Contraceptive failure | Induction of glucuronyl transferase by nelfinavir; inhibition of CYP450 3A4 by nelfinavir | Use alternative method of birth control  *Alternative Agents*:  **Condoms; barrier methods** |
| Fosphenytoin[222](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#222)  (Cerebyx)(Cerebyx) | - | - | - | Not studied; may decrease nelfinavir levels | Decreased nelfinavir effects | Induction of CYP450 3A4 by phenytoin | Dose adjustment not established |
| Indinavir[72](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#72)  (IDV)(Crixivan) | 1200 mg Q12H | 1250 mg Q12H | Indinavir AUC: no significant change (similar to indinavir 800 mg Q8H); indinavir Cmax: no significant change | No significant change | - | - | Indinavir 1200 mg Q12H and nelfinavir 1250 mg Q12H |
| Indinavir[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24),[25](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#25),[26](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#26),[27](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#27),[72](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#72)  (IDV)(Crixivan) | 800 mg Q8H x 7 days | 750 mg x 1 dose | Not studied | Nelfinavir AUC: increased 83%; Cmax: increased 31% | Increased nelfinavir effects | Inhibition of CYP450 3A4 by indinavir | Indinavir 1200 mg Q12H and nelfinavir 1250 mg Q12H |
| Indinavir[254](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#254),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24),[25](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#25),[26](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#26),[27](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#27),[72](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#72)  (IDV)(Crixivan) | 800 mg x 1 dose | 750 mg Q8H x 7 days | Indinavir AUC: increased 51%; AUC of 1000 mg Q12H with nelfinavir was similar to AUC of 800 mg Q8H without nelfinavir | Nelfinavir AUC: increased 83%; Cmax: increased 31% | Increased nelfinavir and indinavir effects | Inhibition of CYP450 3A4 by both drugs | Dose adjustment not established; may consider indinavir 1000-1200 mg Q12H when coadminstered with nelfinavir 1000-1250 mg Q12H |
| Indinavir[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (IDV)(Crixivan) | 800 mg x 1 dose | 750 mg x 7 days | Indinavir AUC: increased 51%; Cmax: no significant change | Not studied | Increased indinavir effects | Inhibition of CYP450 3A4 by nelfinavir | Indinavir 1200 mg Q12H and nelfinavir 1250 mg Q12H |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Nelfinavir** | **Effect on Drug Levels** | **Effect on Nelfinavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ketoconazole[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Nizoral) | 400 mg QD x 7 days | 500 mg Q8H x 5-6 days | - | AUC: increased 35%; Cmax: increased 25% | Increased nelfinavir effects | Inhibition of CYP450 3A4 by ketoconazole | No dose adjustment necessary |
| Lamivudine[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (3TC)(Epivir) | 150 mg x 1 dose | 750 mg Q8h x 7-10 days | Lamivudine AUC: no significant change; Cmax: increased 31% | Not studied | Increased lamivudine effects | - | No dose adjustment necessary |
| Lopinavir/ritonavir[11](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#11)  (LPV/r)(Kaletra) | 400/100 mg BID | 1250 mg BID | Lopinavir Cmax: decreased 21%; AUC: decreased 27%; Cmin: decreased 33%. Ritonavir Cmax: decreased 26%; AUC: decreased 24%; Cmin: decreased 29% | Nelfinavir Cmax: no significant change; AUC: no significant change; Cmin: increased 113% | Decreased lopinavir/ritonavir effects | Induction of P450 3A4 by lopinavir/ritonavir and nelfinavir | Dose adjustment not established |
| Lovastatin[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Mevacor)(Mevacor) | - | - | Not studied; may increase lovastatin levels | - | Increased lovastatin effects (eg, myopathy, rhabdomyolysis) | Inhibition of CYP450 3A4 by nelfinavir | Do not coadminister  *Alternative Agents*:  **Atorvastatin Pravastatin** |
| Marijuana[171](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#171)  (Pot, THC) | 4% THC cigarettes or 2.5 mg dronabinol TID | 750 mg TID | - | Nelfinavir AUC: no significant change; Cmax: decreased 17%; Cmin: no significant change | - | Possible induction of CYP450 3A4 by cannabinoids | No dose adjustment necessary |
| Medroxyprogesterone acetate[393](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#393)  (Depo-Provera) | 150 mg | - | Progesterone levels: no significant change | Nelfinavir AUC: no significant change; M8 AUC: no significant change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Nelfinavir** | **Effect on Drug Levels** | **Effect on Nelfinavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Methadone[199](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#199),[200](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#200)  (Dolophine)(Dolophine) | 10 to 40 mg QD x 1 month | 1250 mg BID x 8 days | Decreased methadone and methadone metabolite exposure | - | Withdrawal symptoms not observed | Induction of CYP450 3A4 by nelfinavir | Monitor and adjust methadone as indicated |
| Methadone[201](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#201)  (Dolophine)(Dolophine) | 40-120 mg QD x 4 weeks | 1250 mg BID x 5 days | - | Cmin: increased 300% | Not clinically significant | Inhibition of nelfinavir metabolism by methadone | No dose adjustment necessary |
| Midazolam[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Versed) | - | - | Not studied; may increase midazolam levels | - | Increased midazolam effects (eg, increased sedation, confusion, respiratory depression) | Inhibition of CYP450 3A4 by nelfinavir | Parenteral midazolam can be used with caution when given as a single dose in a monitored situation for procedural sedation; chronic midazolam administration (oral or intravenous) should be avoided  *Alternative Agents*:  **Lorazepam** |
| Nevirapine[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24),[73](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#73),[74](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#74)  (NVP)(Viramune) | 200 mg QD x 14 days, 200 mg BID x 14 days | 750 mg TID x 36 days | Not studied | No significant change | - | - | No dose adjustment necessary |
| Norethindrone[402](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#402)  (Micronor)(Micronor) | 0.4 mg QD x 15 days | 750 mg Q8H x 7 days | Norethindrone AUC: decreased 18% | - | - | - | Use alternative method of birth control |
| Omeprazole[245](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#245)  (Prilosec)(Prilosec) | 40 mg QD x 4 days | 1250 mg BID x 8 days with 1 week washout period after 4 days | - | Nelfinavir AUC: decreased 36%; Cmax: decreased 37%; Cmin: decreased 39%;M8 AUC: decreased 92%; Cmax: decreased 89%; Cmin: decreased 75% | Decreased nelfinavir effects | - | Do not coadminister |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Nelfinavir** | **Effect on Drug Levels** | **Effect on Nelfinavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Phenobarbital[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Luminal, others)(Luminal) | - | - | - | Not studied; may decrease nelfinavir levels | Decreased nelfinavir effects | Induction of CYP450 3A4 by phenobarbital | Avoid combination if possible; consider alternative agents; monitor phenobarbital levels and adjust as indicated  *Alternative Agents*:  **Gabapentin Lamotrigine Tiagabine Topiramate** |
| Phenytoin[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24),[226](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#226),[227](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#227)  (Dilantin) | 300 mg QAM | 1250 mg BID | Phenytoin Cmax: decreased 21%; AUC: decreased 30%; Cmin: decreased 39% | Nelfinavir: no significant change; M8 levels: decreased 20-30% | Decreased phenytoin effects | Induction of CYP450 3A4 by phenytoin | Avoid combination if possible; consider alternative agents; monitor phenytoin levels and adjust as indicated  *Alternative Agents*:  **Gabapentin Lamotrigine Tiagabine Topiramate** |
| Pimozide[177](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#177)  (Orap)(Orap) | - | - | Not studied; may increase pimozide levels | - | Increased pimozide effects (eg, hypotension, cardiac arrhythmias) | Inhibition of CYP450 3A4 by nelfinavir | Do not coadminister |
| Pravastatin[215](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#215)  (Pravachol)(Pravachol) | 40 mg QD on days 15-18 | 1250 mg BID on days 1-18 | Not studied | Nelfinavir AUC: no significant change; Cmin: increased 61%; M8 AUC: no significant change; M8 Cmin: increased 31% | - | Unknown | No dose adjustment necessary |
| Pravastatin[214](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#214)  (Pravachol)(Pravachol) | Not reported | Not reported | Pravastatin AUC: decreased 47% | Not reported | Decreased pravastatin effects | Possible induction of CYP450 by nelfinavir | May need to titrate pravastatin dose to effect in order to reach lipid goals |
| Quinidine[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Quindex, others)(Quindex) | - | - | May increase quinidine levels | - | Increased quinidine effects (eg, cardiac arrhythmias) | Inhibition of CYP450 3A4 by nelfinavir | Do not coadminister |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Nelfinavir** | **Effect on Drug Levels** | **Effect on Nelfinavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Rifabutin[345](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#345),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Mycobutin)(Mycobutin) | 150 mg QD x 8 days | 750 mg Q8H x 7-8 days | Rifabutin AUC: increased 83%; Cmax: increased 19% | Nelfinavir AUC: decreased 23%; Cmax: decreased 18% | Increased rifabutin effects (eg, uveitis); decreased nelfinavir effects | Inhibition of CYP450 3A4 by nelfinavir; induction of CYP450 3A4 by rifabutin | Decrease rifabutin to 150 mg QD or 300 mg 2 to 3 times/week and increase nelfinavir to 1000 mg TID |
| Rifabutin[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Mycobutin)(Mycobutin) | 150 mg QD x 8 days | 1250 mg Q12H x 7-8 days | - | No significant change | - | - | Decrease rifabutin to 150 mg QD or 300 mg 2 to 3 times/week and increase nelfinavir to 1000 mg TID |
| Rifabutin[345](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#345),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Mycobutin)(Mycobutin) | 300 mg QD x 8 days | 750 mg Q8H x 7-8 days | Rifabutin AUC: increased 207%; Cmax: increased 146% | Nelfinavir AUC: decreased 32%; Cmax: decreased 25% | Increased rifabutin effects (eg, uveitis); decreased nelfinavir effects | Inhibition of CYP450 3A4 by nelfinavir; induction of CYP450 3A4 by rifabutin | Decrease rifabutin to 150 mg QD or 300 mg 2 to 3 times/week and increase nelfinavir to 1000 mg TID |
| Rifampin[254](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#254),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Rifampicin)(Rifadin) | 600 mg QD x 8 days | 750 mg Q8H x 5-6 days | - | Nelfinavir AUC: decreased 82%; Cmax: decreased 76% | Decreased nelfinavir effects | Induction of CYP450 3A4 by rifampin | Do not coadminister  *Alternative Agents*:  **Rifabutin** |
| Rifapentine[336](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#336)  (Priftin)(Priftin) | - | - | - | Not studied; may decrease nelfinavir levels | Decreased nelfinavir effects | Induction of CYP450 3A4 by rifapentine | Do not coadminister  *Alternative Agents*:  **Rifabutin** |
| Ritonavir[107](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#107)  (RTV)(Norvir) | 100 mg or 200 mg BID on days 15-31 | 1250 mg BID on days 1-31 | Not studied | Nelfinavir AUC: increased 17-27% (on ritonavir 100 mg BID); M8 AUC: increased 67-82% (on ritonavir 100 mg BID); nelfinavir AUC: increased 20-53% (on ritonavir 200 mg BID); M8 AUC: increased 69-87% (on ritonavir 200 mg BID) | - | Inhibition of CYP450 3A4 by both ritonavir and nelfinavir | Dose adjustment not established |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Nelfinavir** | **Effect on Drug Levels** | **Effect on Nelfinavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Ritonavir[77](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#77)  (RTV)(Norvir) | 200 mg or 400 mg QD with food x 15 days | 2000 mg/ritonavir 200 mg, 2000 mg/ritonavir 400 mg, or 2500 mg/200 mg QD with food x 15 days | - | Nelfinavir 2000 mg/ritonavir 200 mg AUC: increased 100%; Cmax: increased 95%; Cmin: increased 92% (all values are compared to nelfinavir 1250 mg BID) | - | Inhibition of CYP450 3A4 by ritonavir | Using nelfinavir 2000 mg/ritonavir 200 mg QD with food may allow for QD dosing |
| Ritonavir[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (RTV)(Norvir) | 500 mg Q12H x 3 doses | 750 mg x 1 dose | Not studied | Nelfinavir AUC: increased 152%; Cmax: increased 44% | Increased nelfinavir effects | Inhibition of CYP450 3A4 by ritonavir | No dose adjustment necessary |
| Ritonavir[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (RTV)(Norvir) | 500 mg x 1 dose | 750 mg Q8H x 5 dose | No significant change | - | - | - | No dose adjustment necessary |
| Saquinavir[147](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#147)  (SQV)(Fortovase, Invirase) | 1000 mg saquinavir BID with 100 mg ritonavir BID on days 1-14 | 1250 mg BID on days 16-21 | Saquinavir Cmax: increased 172% | Nelfinavir Cmax: increased 55%; M8 AUC: increased 622%; Cmax: increased 94%; Cmin: increased 179% | - | Inhibition of CYP450 3A4 by saquinavir/ritonavir | No dose adjustment necessary |
| Saquinavir[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24),[75](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#75)  (SQV)(Fortovase, Invirase) | 1200 mg (soft gel cap) x 1 dose | 750 mg TID x 4 days | Saquinavir AUC: increased 392%; Cmax: increased 179% | - | Increased saquinavir effects | Inhibition of CYP450 3A4 by nelfinavir | May consider saquinavir 800 mg TID with nelfinavir 750 mg TID or saquinavir 1200 mg BID with nelfinavir 1250 mg BID |
| Saquinavir[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24),[75](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#75)  (SQV)(Fortovase, Invirase) | 1200 mg (soft gel caps) TID x 4 days | 750 mg x 1 dose | Not studied | Nelfinavir AUC: increased 18%; Cmax: no change | - | - | No dose adjustment necessary |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Nelfinavir** | **Effect on Drug Levels** | **Effect on Nelfinavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Saquinavir[45](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#45),[46](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#46)  (SQV)(Fortovase, Invirase) | 1200 mg TID x 4 days (1200 mg single dose) | 750 mg (single dose) x 4 days | Saquinavir AUC: increased 392% | Nelfinavir AUC: increased 18% | - | Inhibition of CYP450 3A4 by both drugs | Decrease saquinavir to 800 mg TID or 1200 mg BID; no change in nelfinavir dose necessary |
| Sildenafil[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Viagra) | - | - | Not studied; may increase sildenafil levels | - | Increased sildenafil effects (eg, hypotension, priapism) | Inhibition of CYP450 3A4 by nelfinavir | Initiate sildenafil at 25 mg QOD-QD; adjust dose as indicated; not recommended to exceed 25 mg in a 48 hour period |
| Sildenafil[298](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#298)  (Viagra) | 25 mg x 1 | 1250 mg Q12H | No significant change | Not studied | - | - | No dose adjustment necessary |
| Simeprevir[727](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#727)  (Olysio) | - | - | - | - | - | Inhibition of CYP3A4 potentiating simeprevir effects | Do not coadminister |
| Simvastatin[219](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#219),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Zocor)(Zocor) | - | - | Simvastatin AUC: increased 506%; Cmax: increased 517% | No significant change | Increased simvastatin effects (eg, myopathy, rhabdomyolysis) | Inhibition of CYP450 3A4 by nelfinavir | Do not coadminister  *Alternative Agents*:  **Atorvastatin Pravastatin** |
| St. John's Wort[173](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#173),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Hypericum perforatum, hypericin, hyperforin) | - | - | - | May decrease nelfinavir levels | Decreased nelfinavir effects | Induction of CYP450 3A4 by St. John's wort | Do not coadminister |
| **Coadministered Drug** | **Dose of Drug** | **Dose of Nelfinavir** | **Effect on Drug Levels** | **Effect on Nelfinavir Levels** | **Potential Clinical Effects** | **Mechanism of Interaction** | **Management** |
| Stavudine[86](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#86)  (d4T)(Zerit) | - | - | - | - | - | - | No dose adjustment necessary |
| Stavudine[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (d4T)(Zerit) | 30 mg to 40 mg BID x 56 days | 750 mg TID x 56 days | No significant change | Not studied | - | - | No dose adjustment necessary |
| Tacrolimus[306](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#306),[305](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#305),[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Prograf)(Prograf) | - | - | Increased tacrolimus levels | - | Increased tacrolimus effects (eg, increased bone marrow suppression) | Inhibition of CYP450 3A4 by nelfinavir | Monitor and adjust tacrolimus as indicated |
| Terfenadine[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Seldane)(Seldane) | - | - | Not studied; may increase terfenadine levels | - | Increased terfenadine effects (eg, cardiac arrhythmias) | Inhibition of CYP450 3A4 by nelfinavir | Do not coadminister  *Alternative Agents*:  **Cetirizine Fexofenadine Loratadine** |
| Triazolam[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (Halcion) | - | - | Not studied; may increase triazolam levels | - | Inceased triazolam effects (increased sedation, confusion, respiratory depression) | Inhibition of CYP450 3A4 by nelfinavir | Do not coadminister; consider alternative agents  *Alternative Agents*:  **Lorazepam Oxazepam Temazepam Trazodone** |
| Zidovudine[24](http://arv.ucsf.edu/insite?page=ar-00-02&param=12&post=4#24)  (AZT, ZDV)(Retrovir) | 200 mg x 1 dose | 750 mg Q8H x 7-10 days | Zidovudine AUC: decreased 35%; Cmax: decreased 31% | Not studied | - | - | No dose adjustment necessary |
| "-" indicates that there are no data available | | | | | | | |

|  |  |
| --- | --- |
| 11: | Klein C, Bertz R, Ashbrenner E, et al. Assessment of the multiple-dose pharmacokinetic interaction of lopinavir/ritonavir with nelfinavir [abstract #536]. 10th Conference on Retroviruses and Opportunistic Infections; 2003 February 10-14; Boston, Massachusetts. |
| 19: | Videx [package insert]. Princeton, NJ: Bristol-Myers Squibb Co.; 2003. |
| 21: | Sustiva [package insert]. Wilmington, DE: DuPont Pharmaceuticals Co.; 2003. |
| 24: | Viracept [package insert]. La Jolla, CA: Agouron Pharmaceuticals, Inc.; Sept 2004. |
| 25: | Yuen G, Anderson R, Daniels R, et al. Investigations of nelfinavir mesylate pharmacokinetic interactions with indinavir and ritonavir [abstract #428]. 4th Conference on Retroviruses and Opportunistic Infections; 1997 Jan 28-Feb 1; Washington, D.C. |
| 26: | Havlir DV, Riddler S, Squires K, et al. Co-administration of indinavir and nelfinavir in a twice daily regimen: preliminary safety, pharmacokinetic and anti-viral activity results [abstract #393]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, Illinois. |
| 27: | Squires K, Riddler S, Havlir D, et al. Co-administration of indinavir 1000 mg and with escalating nelfinavir dose in a twice daily regimen: preliminary safety, pharmacokinetic and anti-viral activity. 36th Annual Meeting of the Infectious Diseases Society of America; 1998 Nov 11-14; Denver, Colorado. |
| 45: | Kearney BP, Reul T, Coleman R, et al. Pharmacokinetics of adefovir dipivoxil in combination with saquinavir, indinavir, efavirenz, delavirdine, didanosine, or lamivudine in normal volunteers [abstract #86]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco, California. |
| 46: | Moyle G, Pozniak A,Opravil M, et al. The SPICE study: 48-week activity of combinations of saquinavir soft gelatin and nelfinavir with and without nucleoside analogues. Study of Protease Inhibitor Combinations in Europe. J Acquir Immune Defic Syndr 2000;23(2):128-37. |
| 60: | Agenerase [package insert]. Research Triangle Park, NC: Glaxo Wellcome Inc; 2004. |
| 70: | Villani, et al. Pharmacokinetics of efavirenz alone and in combination therapy with nelfinavir in HIV-1 infected patients. Br J Clin Pharmacol 1999;48:712-15. |
| 71: | Fiske WD, Benedek SJ, White SJ, et al. Pharmacokinetic interaction between efavirenz and nelfinavir mesylate in healthy volunteers [abstract #349]. 5th Conference on Retroviruses and Opportunistic Infections; 1998 Feb 1-5; Chicago, Illinois. |
| 72: | Squires K, Riddler S, Havlir D, et al. Co-administration of indinavir 1200 mg with nelfinavir 1250 mg in a twice daily regimen: preliminary safety, PK activity. 6th Conference on Retroviruses and Opportunistic Infections; 1999 Jan 31-Feb 4; Chicago, Illinois. |
| 73: | Skowron G, Leoung G, Kerr B, et al. Lack of pharmacokinetic interaction between nelfinavir and nevirapine. Aids 1998;12(10):1243-44. |
| 74: | Vilaro J, Mascaro J, Colomer J, et al. The pharmacokinetics of combination therapy with nelfinavir (NFV) plus neviarapine (NVP) in HIV positive patients [abstract #A-497]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois. |
| 75: | Invirase [package insert]. Roche Laboratories Inc, Nutley, NJ, 2007. |
| 77: | Aarnoutse R, Burger D, van Oosterhout J, et al. Multiple dose pharmacokinetics (PK) and tolerability of once daily (OD) nelfinavir (NFV) and ritonavir combinations in healthy volunteers [abstract #1.3]. 2nd International Workshop on Clinical Pharmacology of HIV Therapy; 2001 April 2-4; Noordwijk, the Netherlands. |
| 86: | Zerit [package insert]. Princeton, NJ: Bristol-Myers Squibb Immunology; Sept 2005. |
| 89: | Cox SR, Schneck DW, Herman BD, et al. Delavirdine (DLV) and nelfinavir (NFV): a pharmacokinetic (PK) drug-drug interaction study in healthy adult volunteers [abstract #345]. 5th Conference on Retroviruses and Opportunistic Infections. Feb 1-5, 1998. Chicago, Illinois. |
| 107: | Kurowski M, Kaeser B, Sawyer A, et al. Low-dose ritonavir moderately enhances nelfinavir exposure. Clin Pharmacol Ther 2002;72:123-32. |
| 111: | Pfister M, Labbe L, Lu J-F, et al. Effect of coadministration of nelfinavir, indinavir and saquinavir on the pharmacokinetics of amprenavir. Clin Pharmacol Ther 2002;72:133-41. |
| 147: | Stocker H, Kruse G, Arasteh K, et al. Pharmacokinetic interaction between saquinavir/ritonavir and nelfinavir in HIV-infected patients [abstract A-454]. 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004 Oct 30-Nov 2; Washington, D.C. |
| 156: | Labbe L, Sheiner LB, Smith PF, et al. Effect of co-administration of efavirenz on the pharmacokinetics of nelfinavir and its active metabolite, M8 in ACTG 384 [abst. 22]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 April 28-30; Quebec City, Canada. |
| 157: | Kurowski M, Molto J, Breske G, et al. Atazanavir enhances trough concentrations of nelfinavir and its M8 metabolite in a treatment regimen without ritonavir [abst. 90]. 6th International Workshop on Clinical Pharmacology of HIV Therapy; 2005 April 28-30; Quebec City, Canada. |
| 171: | Kosel B, Aweeka FT, Benowitz NL, et al. The effects of cannabinoids on the pharmacokinetics of indinavir and nelfinavir. AIDS 2002;16:543-50. |
| 173: | Piscitelli SC, Burstein AH, Chaitt D, et al. Indinavir concentrations and St. John's wort. [letter] Lancet. 2000;355:547-548. |
| 177: | Orap [package insert]. Sellersville, PA: Teva Pharmaceuticals; 1999. |
| 199: | Hsyu PH, Lillibridge JH, Maroldo L, et al. Pharmacokinetic and pharmacodynamic interactions between nelfinavir and methadone [abstract #87]. 7th Conference on Retroviruses and Opportunistic Infections; 2000 Jan 30-Feb 2; San Francisco, California. |
| 200: | McCance-Katz EF, Farber S, Selwyn PA, et al. Decrease in methadone levels with nelfinavir mesylate. Am J Psychiatry 2000;157(3):481. |
| 201: | Smith PF, Booker BM, Difrancesco R, et al. Effect of methadone or LAAM on the pharmacokinetics of nelfinavir and M8 [abstract #A-491]. 41st Interscience Conference on Antimicrobial Agents and Chemotherapy; 2001 December 16-19; Chicago, Illinois. |
| 214: | Gerber JG, Rosenkranz S, Fichtenbaum CJ, et al. The effect of efavirenz and nelfinavir on the pharmacokinetics of pravastatin [abst 870]. 2nd International Conference on HIV Pathogenesis and Treatment; 2003 July 13-16; Paris, France. |
| 215: | Fichtenbaum CJ, Gerber JG, Rosenkranz SL, et al. Pharmacokinetic interaction between protease inhibitors and statins in HIV seronegative volunteers: ACTG study A5047. AIDS 2002;16:569-77. |
| 219: | Hsyu PH, Schultz-Smith MD, Lillibridge JH, et al. Pharmacokinetic interactions between nelfinavir and 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors atorvastatin and simvastatin. Antimicrob Agents Chemother 2001;45:3445-50. |
| 222: | Cerebyx [package insert]. Morris Plains, NJ: Parke-Davis; 1999. |
| 226: | Shelton MJ, Cloen D, Becker M, et al. Evaluation of the pharmacokinetic (PK) interaction between phenytoin (Phen) and nelfinavir (NFV) in healthy volunteers at steady state [abstract #426]. 40th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2000 September 17-20; Toronto, Canada. |
| 227: | Honda, et al. A generalized seizure following infection suspected due to interaction between nelfinavir and phenytoin. Intern Med 1999;38(3):302-3. |
| 245: | Fang A, Damle B, Labadie R, et al. Significant decrease nelfinavir systemic exposure after omeprazole coadministration in healthy subjects. Pharmacotherapy 2008; 28: 42-50. |
| 254: | CDC. Guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. Jan 28, 2000. [AIDS Treatment Information Service: Current Treatment] Available at: http://www.hivatis.org/trtgdlns.html. |
| 260: | von Moltke LL, Greenblatt DJ, Duan SX, et al. Inhibition of desipramine hydroxylation (Cytochrome P450-2D6) in vitro by quinidine and by viral protease inhibitors: relation to drug interactions in vivo. J Pharm Sci 1998;87:1184-9. |
| 267: | Blum, et al. A pharmacokinetic interaction evaluation of MKC-442 and nelfinavir in healthy male and female volunteers [abstract]. 12th International Conference on AIDS; 1998 June 28-July 3; Geneva, Switzerland. |
| 294: | Propulsid [package insert]. Titusville, NJ: Janssen Pharmaceutica; 2000 |
| 298: | Bratt G, Stahle L. Silfenavil does not alter nelfinavir pharmacokinetics. Ther Drug Monit 2003;25:240-2. |
| 305: | Sheikh AM, Wolf DC, Lebovics E, et al. Concomitant human immunodeficiency virus protease inhibitor therapy markedly reduced tacrolimus metabolism and increases blood levels. Transplantation 1999;68:307-9. |
| 306: | Schvarcz R, et al. Interaction between nelfinavir and tacrolimus after orthoptic liver transplantation in a patient coinfected with HIV an hepatitis C virus (HCV). Transplantaion. 2000;69(10):2194-5 |
| 316: | Tikosyn [package insert]. New York, NY: Pfizer; 1999. |
| 336: | Prifitin [package insert]. Kansas City, MO: Hoechst Marion Roussel, Inc,; 1998. |
| 345: | CDC. Notice to readers: Updated guidelines for the use of rifabutin or rifampin for the treatment and prevention of tuberculosis among HIV-infected individuals taking protease inhibitors or nonnucleoside reverse transcriptase inhibitors. MMWR 2000;49:185-9. |
| 384: | Stone JA, Migoya E, Hickey L, et al. Potential for interactoons between caspofungin and nelfinavir or rifampin. Antimicrob Agents Chemother 2004; 48: 4306-14. |
| 393: | Cohn SE, Watts D, Lertora J, et al. An open-label, non-randomized study of the effect of depo-medroxyprogesterone acetate on the pharmacokinetics of selected protease inhibitors and non-nucleoside reverse transcriptase inhibitors therapies among HIV-infected women [abst. #82} 12th Conference on Retroviruses and Opportunistic Infections; 2005 February 22-25; Boston, Massachusetts. |
| 402: | Viracept [package insert]. La Jolla, CA: Agouron Pharmaceuticals, Inc.; Sept 2004. |
| 559: | Colcrys [package insert]. Philadelphia, PA: URL Pharma, Inc., May 2010 |
| 727: | Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/contentfiles/lvguidelines/AdultandAdolescentGL.pdf. |